Using Approved CAR-T Cancer Treatments Earlier Supported by Adcomm

Despite a potential increase in the risk of death, the FDA’s Oncologic Drugs Advisory Committee voted Friday in support of two already approved multiple myeloma CART-T cell treatments in earlier stages of the disease.

The committee unanimously supported Johnson and Johnson’s Carvykti (cilta-cel) for patients who have already had at least one prior line of treatment; Carvykti is already approved as a fifth-line therapy.

Although less enthusiastic about Bristol Myers Squibb’s Abecma (idecabtagene vicleucel), the committee agreed by a vote of 8-3 that its benefit outweighed its risks when used as a third-line treatment for the disease — it’s currently approved as a fifth-line therapy.

To read the whole story, click here to subscribe.

Related Topics